Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from EPS Creative Health Technology Group Limited ( (HK:3860) ).
EPS Creative Health Technology Group Limited has announced two significant agreements involving its subsidiaries. The company operates in the health technology sector, focusing on providing contract research organization (CRO) services and leasing equipment. The CRO Services Framework Agreement involves EP-Bio providing CRO services to Shanghai EPS and Beijing Global for three financial years ending in 2028. The Lease Framework Agreement involves EP Trading leasing equipment to several subsidiaries for the same period. These agreements are considered continuing connected transactions under Hong Kong’s Listing Rules, subject to reporting and annual review requirements but exempt from independent shareholders’ approval.
The most recent analyst rating on (HK:3860) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on EPS Creative Health Technology Group Limited stock, see the HK:3860 Stock Forecast page.
More about EPS Creative Health Technology Group Limited
Average Trading Volume: 290,238
Technical Sentiment Signal: Sell
Current Market Cap: HK$250.6M
For an in-depth examination of 3860 stock, go to TipRanks’ Overview page.